Rifampin clinical trials
Rifampin is named as an intervention in 8 current clinical trials in our China, Canada, India, Brazil, Mexico and Australia registers. 4 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Johns Hopkins University (1). The most-studied condition is Tuberculosis.
Where Rifampin is approved
All regulators →Of the three regulators tracked here, the first to approve Rifampin was the US, on 21 May 1971.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Rifampin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Rifampin works
All drug targets →- Bacterial DNA-directed RNA polymerase inhibitor InhibitorChEMBL only
- Alzheimer diseasePhase 3
- HIV infectious diseasePhase 3
- SepsisPhase 3
- Anterior uveitisPhase 3
- Drug-resistant tuberculosisPhase 3
- Hidradenitis suppurativaPhase 3
- InfectionPhase 3
- Infective endocarditisPhase 3
- MeningitisPhase 3
- Multiple system atrophyPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL374478, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2765, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Rifampin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Rifampin
- ATC code
- J04AB02
- ChEMBL
- CHEMBL374478
- DrugBank
- DB01045
- PubChem CID
- 136262914
- CAS number
- 13292-46-1
- FDA UNII
- VJT6J7R4TR
- Wikidata
- Q422652
- Wikipedia
- Rifampicin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Rifampin
8 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Rifampin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Supply shortages
- Rifampin InjectionUS (FDA) · Current · updated 3 Nov 2026
- Rifampin CapsuleUS (FDA) · Current · updated 3 Nov 2026
Conditions studied with Rifampin
11 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Johns Hopkins University | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Shandong University | 1 |
| Jiangsu Simcere Pharmaceutical Co., Ltd | 1 |
| MindRank AI Ltd | 1 |
| Centers for Disease Control and Prevention | 1 |
| Bristol-Myers Squibb | 1 |
| Oregon Health and Science University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 1 |
| Clinical trials in Canada | 3 | 2 |
| Clinical trials in India | 2 | 1 |
| Clinical trials in Brazil | 1 | 0 |
| Clinical trials in Mexico | 1 | 0 |
| Clinical trials in Australia | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Rifampin trials
How many clinical trials are testing Rifampin?
8 current trials in our China, Canada, India, Brazil, Mexico and Australia registers name Rifampin as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Rifampin trials recruiting patients?
Yes. 4 of the 8 trials are recruiting: 1 with sites in China, 2 with sites in Canada and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rifampin clinical trials?
Johns Hopkins University (1), National Institute of Allergy and Infectious Diseases (NIAID) (1), Shandong University (1) and Jiangsu Simcere Pharmaceutical Co., Ltd (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is there a Rifampin shortage?
The registers we track list 2 entries for Rifampin: US FDA: current; US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rifampin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rifampin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rifampin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.